ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ViiV Healthcare's Dovato approved in US as first two-drug single-tablet regimen for patients with treatment-naïve HIV
April 09, 2019The FDA on Monday announced the approval of ViiV Healthcare's Dovato (dolutegravir/lamivudine) for ^ -
ViiV announces long-term positive results for Juluca combination
April 09, 2019London-based ViiV Healthcare has announced three-year results from its Sword-1 and Sword-2 trials. -
Viiv files HIV drug patent infringement lawsuit against Gilead
February 11, 2018GSK-owned Viiv healthcare has filed a lawsuit against Gilead, the American biopharma company, for an alleged patent infringement of an HIV drug which has been newly approved. -
FDA approves two-drug regimen, JULUCA for the Treatment of HIV-1 Infection
November 23, 2017HIV patients have a new maintenance drug in their arsenal of medication. -
ViiV Healthcare submits regulatory applications for HIV two-drug regimen
June 07, 2017GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, have announced regulatory submissions... -
ViiV study shows efficacy of two-drug HIV regimen
February 16, 2017ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science's rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients
Pharma Sources Insight January 2025
